Trial Profile
Evaluation of Efficiency of Secretin-Assisted Computed Tomography Scan and Secretin-Assisted Magnetic Resonance Imaging in Improving Pancreatic Enhancement and Tumor Conspicuity: Prospective Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Secretin (Primary)
- Indications Pancreatic cancer
- Focus Diagnostic use
- 13 Jun 2022 Status changed from recruiting to withdrawn prior to enrolment.
- 30 Sep 2014 New trial record